etoposide has been researched along with hydroxyurea in 91 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (7.69) | 18.7374 |
| 1990's | 33 (36.26) | 18.2507 |
| 2000's | 33 (36.26) | 29.6817 |
| 2010's | 14 (15.38) | 24.3611 |
| 2020's | 4 (4.40) | 2.80 |
| Authors | Studies |
|---|---|
| Hansch, C; Khwaja, TA; Selassie, CD | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Armitage, JO; Bierman, PJ; Glenn, LD; Kessinger, A; Reed, EC; Vaughan, WP | 1 |
| Lihou, MG; Smith, PJ; Tomlinson, FH | 1 |
| de Vries, EG; Smit, AJ; van Essen, LH | 1 |
| Alexander, RB; Coffey, DS; Nelson, WG | 1 |
| Covey, JM; Holm, C; Kerrigan, D; Pommier, Y | 1 |
| Bolis, G; Bonazzi, C; Landoni, F; Mangili, G; Mangioni, C; Vergadoro, F; Zanaboni, F | 1 |
| Ratain, MJ; Schilsky, RL; Senekjian, EK; Simon, T; Vogelzang, NJ; Wojack, BR | 1 |
| Crowther, D; Gasser, AB; Scarffe, JH; Steward, WP; Wagstaff, J | 1 |
| Vogelzang, NJ | 1 |
| Bellamy, AS; Hill, BT | 1 |
| Kato, M; Takada, S; Takayama, S | 1 |
| Hendrick, A | 1 |
| Beere, HM; Chapman, RS; Chresta, CM; Dive, C; Heer, S; Herberg, AA; Hickman, JA; Whetton, AD | 1 |
| Aster, JC; Inhorn, RC; Roach, SA; Slapak, CA; Soiffer, R; Stone, RM; Tantravahi, R | 1 |
| Armitage, JO; Bierman, PJ; Gwilt, P; Kris, E; Vaughan, WP; Vose, J | 1 |
| Alexander, IE; Miller, AD; Russell, DW | 1 |
| Berger, NA; Chatterjee, S; Cheng, MF | 1 |
| Bayly, AC; Dive, C; Roberts, RA | 1 |
| Akkoc, N; Altungoz, O; Cehreli, C; Onvural, B; Undar, B | 1 |
| Kietlińska, Z; Sablińska, B; Zieliński, J | 1 |
| Bauters, F; Fenaux, P; Lovi, V; Morschhauser, F; Pagniez, D; Rose, C; Wattel, E | 1 |
| Aggarwal, BB; Gallati, H; Loetscher, H; Mihalik, R; Penzes, M; Pocsik, E | 1 |
| Berman, M; Blessing, JA; Burke, TW; Currie, J; Fowler, J; Muss, HB | 1 |
| Berman, M; Blessing, JA; Currie, JL; McGehee, R; Soper, JT | 1 |
| Copplestone, A; Couteaux, ME; Deconinck, E; Economopoulos, T; Fenaux, P; Foussard, C; Guerci, A; Hecquet, B; Mahé, B; Michaux, JL; Mufti, G; Oscier, D; Pegourié, B; Resegotti, L; Stoppa, AM; Voglova, V; Wattel, E | 1 |
| Carella, AM; Frassoni, F | 1 |
| Fujita, S; Hasegawa, A; Hasegawa, H; Hato, T; Ninomiya, H; Takada, K; Yanagisawa, K; Yasukawa, M | 1 |
| Cannistra, SA; Korsmeyer, S; Strobel, T; Swanson, L | 1 |
| Behar, C; Bertrand, Y; Dhooge, C; Lutz, P; Machinaud-Lacroix, F; Marguerite, F; Mazingue, F; Otten, J; Philippe, N; Plouvier, E; Rialland, X; Rubie, C; Souillet, G; Vilmer, E; Zix-Kieffer, I | 1 |
| Grillot, DA; Nuñez, G; Simonian, PL | 1 |
| Akiyama, Y; Furusho, K; Kataoka, A; Koishi, S; Kubota, M; Lin, YW; Sawada, M; Usami, I; Watanabe, Ki | 1 |
| Azuma, E; Higashigawa, M; Hirayama, M; Hori, H; Ido, M; Kawasaki, H; Sakurai, M | 1 |
| Akiyama, Y; Furusho, K; Kataoka, A; Kitoh, T; Koishi, S; Kubota, M; Lin, YW; Sawada, M; Usami, I; Watanabe, K | 1 |
| Armstrong, MJ; Bradt, CI; Galloway, SM; Greenwood, SK; Hill, RB; Hilliard, CA; Johnson, TE | 1 |
| Boqué, C; Grañena, A | 1 |
| Fukuchi, K; Gomi, K; Nakamaki, T; Tomoyasu, S; Tsuruoka, N | 1 |
| Brockstein, BE; Haraf, DJ; Humerickhouse, R; Vokes, EE | 1 |
| Bagshawe, KD; Bower, M; Foskett, M; Holden, L; Newlands, ES; Rustin, GJ; Short, D | 1 |
| Ohnishi, K | 1 |
| Akutsu, M; Bai, L; Furukawa, Y; Ichikawa, A; Kano, Y; Kon, K; Suzuki, K; Tsunoda, S | 1 |
| Anachkova, B; Gospodinov, A; Kunnev, D; Russev, G | 1 |
| Collins, MK; Gutierrez del Arroyo, A; Palacios, C; Silva, A | 1 |
| Goehle, S; Lamb, JR; Ludlow, C; Simon, JA | 1 |
| Piwnica-Worms, H; Zhao, H | 1 |
| Carella, AM | 1 |
| Alfieri, E; Cirillo, S; D'Amore, R; Fiorillo, A; Greco, N; Maggi, G; Marano, I; Martone, A; Migliorati, R | 1 |
| Akita, S; Akiyama, M; Anderson, KC; Eto, Y; Kanda, N; Kawano, T; Mizoguchi, H; Ohno, T; Yamada, H; Yamada, O | 1 |
| Herrera, P; Jodra, MH; Laraña, JG; López, J; Navarro, JL; Odriozola, J; Pérez de Oteyza, J; Ramos, ML; Ramos, P; Roldán, E; Villalón, L; Zamora, C | 1 |
| Armata, J; Balcerska, A; Bogusławska-Jaworska, J; Boruczkowski, D; Bubała, H; Chybicka, A; Cwiklińska, M; Hicke, A; Kaczmarek-Kanold, M; Kałwak, K; Kolecki, P; Kowalczyk, J; Krauze, A; Matysiak, M; Płoszyńska, A; Rokicka-Milewska, R; Sikorska-Fic, B; Sońta-Jakimczyk, D; Staszak-Kowalska, R; Tomaszewska, R; Turkiewicz, D; Wachowiak, J; Wiśniewska-Slusarz, H; Wysocki, M | 1 |
| Bartolomé-González, B; Fernández-Herrera, J; García-Díez, A; Ruiz-Genao, DP; Sanz-Sánchez, T | 1 |
| Arnaudeau, C; Hansen, LT; Helleday, T; Lundin, C; Mohindra, A; Schultz, N | 1 |
| Blijlevens, N; de Pauw, B; Donnelly, P; Levenga, H; Shirango, H; Verweij, P | 1 |
| Ju, XD; Lou, SQ; Peng, JQ; Tian, H; Wang, WG | 1 |
| Belcourt, MF; Cory, JG; Lin, ZP; Sartorelli, AC | 1 |
| Hirai, I; Sasaki, T; Wang, HG | 1 |
| Garriott, ML; Hoffman, WP; Lee, C; Murphy, GP; Phelps, JB | 1 |
| Ferrara, L; Kmiec, EB; Parekh-Olmedo, H | 1 |
| Bissler, JJ; Dixon, K; Lu, L; Robison, JG | 1 |
| Choi, VW; McCarty, DM; Samulski, RJ | 1 |
| Cedrone, M; Chierichini, A; Diverio, D; Foà, R; Lo Coco, F; Mariani, G; Pasquini, L; Pelosi, E; Peschle, C; Riccioni, R; Rossini, A; Saulle, E; Testa, U; Vitale, A | 1 |
| Attali, B; Bachelin, C; Baron-Van Evercooren, A; Chtarto, A; Girard, C; Lachapelle, F; Salvetti, A; Tenenbaum, L | 1 |
| Bernardini, K; Buratti, T; Lanthaler, AJ; Mitterer, M | 1 |
| Albanese, C; Brotherton, D; Montagnoli, A; Rainoldi, S; Santocanale, C; Tenca, P | 1 |
| Fujita, H; Kurata, M; Maeda, A; Matsushita, A; Mori, M; Nagai, K; Nagai, Y; Takahashi, T; Tanaka, K; Tanaka, Y; Togami, K | 1 |
| DeGregori, J; Marusyk, A | 1 |
| Gottlieb, AB; Seidler, AM | 1 |
| Belfort, P; Braga, A; Consonni, M; Delmanto, LR; Maestá, I; Michelin, OC; Rudge, MV | 1 |
| Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P | 1 |
| Atkinson, HD; Colovic, M; Colovic, N; Jankovic, G; Kraguljac, N; Radojkovic, M; Stanisavljevic, D; Suvajdzic, N; Tomin, D; Vidovic, A | 1 |
| Iland, HJ; Seymour, JF; Wei, A | 1 |
| Bernstein, KA; Godin, SK; Herken, BW; Lee, AG; Mihalevic, MJ; Resnick, MA; Sobol, RW; Westmoreland, JW; Yu, Z; Zhang, Z | 1 |
| Beyer, M; Dietrich, S; Göder, A; Heinzel, T; Kiweler, N; Krämer, OH; Linnebacher, M; Mahboobi, S; Mahendrarajah, N; Nikolova, T; Rauch, A; Reich, TR; Schäfer, C; Schneider, G; Sellmer, A; Sonnemann, J; Stojanovic, N; Tomicic, MT; Wieczorek, M | 1 |
| Borg, C; Deconinck, E; Guenat, D; Merla, G; Rohrlich, PS | 1 |
| Bertolini, F; Cassisa, A; Gasparin, P; Miggiano, MC | 1 |
| Hieda, M; Higashiyama, S; Kikugawa, T; Maekawa, M; Miura, N; Saika, T; Taguchi, T; Watanabe, R | 1 |
| Charoenprasert, K; Chinthammitr, Y; Kasyanan, H; Panoi, N; Phinyo, P; Pongudom, S; Purattanamal, J; Surawong, A; Wongyai, K | 1 |
| Brownridge, PJ; Campbell, AE; Corbin, EK; Eyers, CE; Ferraz Franco, C; Jones, AR; Kalyuzhnyy, A; Perkins, ND; Perkins, S; Su, LI | 1 |
| Chatziantoniou, A; Christodoulou, P; Drenios, C; Ioannou, I; Kourti, M; Zaravinos, A | 1 |
10 review(s) available for etoposide and hydroxyurea
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Continuous infusion chemotherapy: a critical review.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Cycle; Cisplatin; Etoposide; Humans; Hydroxyurea; Infusions, Parenteral; Vinca Alkaloids | 1984 |
A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carboplatin; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Eosinophilia; Etoposide; Fatal Outcome; Female; Humans; Hydroxyurea; Hyperplasia; Ifosfamide; Leukemia, Myeloid; Lymph Nodes; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Pregnancy; Pregnancy Complications, Neoplastic; Remission Induction; Syndrome; Translocation, Genetic; Vincristine | 1995 |
Coexistence of chronic neutrophilic leukemia with light chain myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Doxorubicin; Etoposide; Female; Humans; Hydroxyurea; Immunoglobulin kappa-Chains; Leukemia, Neutrophilic, Chronic; Middle Aged; Multiple Myeloma; Neoplasms, Multiple Primary | 1994 |
[Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia].
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Component Removal; Busulfan; Cisplatin; Combined Modality Therapy; Etoposide; Female; Fusion Proteins, bcr-abl; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Ifosfamide; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 1998 |
Oral 5-FU alternatives for the treatment of head and neck cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Etoposide; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Neoplasm Recurrence, Local; Tegafur; Uracil | 1998 |
[Oral antitumor drugs for hematological malignancies].
Topics: Administration, Oral; Antineoplastic Agents; Cytarabine; Etoposide; Hematologic Neoplasms; Humans; Hydroxyurea; Leukemia-Lymphoma, Adult T-Cell; Piperazines; Prodrugs; Tretinoin | 1999 |
Fatal hemorrhagic pneumonia caused by infection due to Kytococcus sedentarius--a pathogen or passenger?
Topics: Actinomycetales; Actinomycetales Infections; Acyclovir; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bacterial Translocation; Cefepime; Cephalosporins; Clostridium Infections; Colistin; Cytarabine; Daunorubicin; Drug Therapy, Combination; Etoposide; Fatal Outcome; Hemoptysis; Humans; Hydroxyurea; Immunocompromised Host; Intestinal Mucosa; Leukemia, Myeloid, Acute; Male; Metronidazole; Middle Aged; Neutropenia; Pneumonia, Bacterial; Superinfection; Teicoplanin; Trimethoprim, Sulfamethoxazole Drug Combination | 2004 |
Dermatomyositis induced by drug therapy: a review of case reports.
Topics: Adult; Aged; Antibodies, Antinuclear; Autoimmune Diseases; Cyclophosphamide; Dermatomyositis; Etoposide; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Skin | 2008 |
Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
Topics: Adult; Age Factors; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation Factors; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Hydroxyurea; Idarubicin; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Oxides; Platelet Transfusion; Practice Guidelines as Topic; Remission Induction; Risk Assessment; Thioguanine; Treatment Outcome; Tretinoin | 2014 |
7 trial(s) available for etoposide and hydroxyurea
| Article | Year |
|---|---|
Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Drug Synergism; Etoposide; Female; Humans; Hydroxyurea; Leukemia L1210; Male; Mice; Middle Aged; Neoplasms; Tumor Cells, Cultured | 1988 |
Treatment of relapsed non-Hodgkin's lymphoma with a combination of hydroxyurea, ifosfamide, and etoposide.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Etoposide; Female; Humans; Hydroxyurea; Ifosfamide; Lymphoma; Male; Middle Aged; Recurrence | 1985 |
Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mouth Mucosa; Recurrence; Remission Induction; Risk Factors; Stomatitis; Survival Analysis | 1995 |
Combination chemotherapy with hydroxyurea, dacarbazine (DTIC), and etoposide in the treatment of uterine leiomyosarcoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Etoposide; Female; Humans; Hydroxyurea; Leiomyosarcoma; Middle Aged; Survival Analysis; Treatment Outcome; Uterine Neoplasms | 1996 |
Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Etoposide; Female; Humans; Hydroxyurea; Middle Aged; Mixed Tumor, Mesodermal; Neoplasm Recurrence, Local; Treatment Outcome; Uterine Neoplasms | 1996 |
A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group.
Topics: Adult; Aged; Alopecia; Blood Cell Count; Cross-Over Studies; Etoposide; Female; Humans; Hydroxyurea; Karyotyping; Leukemia, Myelomonocytic, Chronic; Life Tables; Male; Middle Aged; Prognosis; Risk Factors; Splenomegaly; Survival Analysis; Treatment Outcome | 1996 |
Efficacy and Safety of Metronomic Chemotherapy Versus Palliative Hydroxyurea in Unfit Acute Myeloid Leukemia Patients: A Multicenter, Open-Label Randomized Controlled Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Follow-Up Studies; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Prognosis; Survival Rate | 2020 |
74 other study(ies) available for etoposide and hydroxyurea
| Article | Year |
|---|---|
Structure-activity relationships of antineoplastic agents in multidrug resistance.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Cricetinae; Dactinomycin; Drug Resistance; Leukemia L1210; Mice; Regression Analysis; Structure-Activity Relationship; Tumor Cells, Cultured | 1990 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
High-dose hydroxyurea in autologous bone marrow transplantation: a promising "new" agent.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carmustine; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Schedule; Etoposide; Humans; Hydroxyurea; Lymphoma, Non-Hodgkin; Middle Aged; Remission Induction; Survival Rate; Thiotepa | 1992 |
Comparison of in vitro activity of epipodophyllotoxins with other chemotherapeutic agents in human medulloblastomas.
Topics: Alkylating Agents; Amsacrine; Cell Division; Cell Survival; Cross-Linking Reagents; Cytarabine; DNA Damage; DNA Topoisomerases, Type II; Drug Resistance; Etoposide; Humans; Hydroxyurea; In Vitro Techniques; Karyotyping; Medulloblastoma; Teniposide; Tumor Cells, Cultured; Vincristine | 1991 |
Successful long-term control of idiopathic hypereosinophilic syndrome with etoposide.
Topics: Adult; Cardiomegaly; Eosinophilia; Etoposide; Humans; Hydroxyurea; Male; Syndrome; Thrombocytopenia | 1991 |
Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II.
Topics: Animals; Bleomycin; Cell Line; Cell Survival; Cytarabine; Dactinomycin; DNA Topoisomerases, Type II; Doxorubicin; Drug Synergism; Etoposide; Fibrosarcoma; Glycoproteins; Hydroxyurea; Mice; Recombinant Proteins; Teniposide; Tumor Necrosis Factor-alpha | 1987 |
Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
Topics: Amsacrine; Animals; Aphidicolin; Camptothecin; Cell Line; Cell Survival; Cricetinae; Cricetulus; Diterpenes; DNA Replication; Etoposide; Hydroxyurea; Kinetics; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1989 |
EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Female; Humans; Hydroxyurea; Methotrexate; Middle Aged; Pregnancy; Pregnancy Complications, Neoplastic; Trophoblastic Neoplasms; Uterine Neoplasms; Vincristine | 1988 |
Murine L5178Y cells resulting in altered drug sensitivities from fractionated radiation exposure in vitro.
Topics: Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Etoposide; Fluorouracil; Hydroxyurea; Leukemia L5178; Leukemia, Experimental; Methotrexate; Mice; Vincristine | 1984 |
Comparison of lesions induced by intra-articular injections of quinolones and compounds damaging cartilage components in rat femoral condyles.
Topics: Administration, Oral; Animals; Bleomycin; Camptothecin; Cartilage, Articular; Chondroitin Lyases; Ciprofloxacin; Collagenases; Cycloheximide; Ethylmaleimide; Etoposide; Fluorescent Dyes; Hydroxyurea; Injections, Intra-Articular; Iodoacetates; Iodoacetic Acid; Irinotecan; Levofloxacin; Male; Ofloxacin; Papain; Rats; Rats, Sprague-Dawley; Rhodamines; Topoisomerase I Inhibitors | 1994 |
Psychosis during interferon in eosinophilic leukaemia.
Topics: Adolescent; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Delusions; Diagnosis, Differential; Epirubicin; Etoposide; Fatal Outcome; Hemibody Irradiation; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Immunologic Factors; Interferon-alpha; Leukemic Infiltration; Male; Palliative Care; Pruritus; Skin; Somatoform Disorders; Splenectomy; Vasculitis; Vincristine | 1994 |
Further characterisation of the in situ terminal deoxynucleotidyl transferase (TdT) assay for the flow cytometric analysis of apoptosis in drug resistant and drug sensitive leukaemic cells.
Topics: Abelson murine leukemia virus; Antineoplastic Agents; Apoptosis; Cell Nucleus; DNA Damage; DNA Nucleotidylexotransferase; DNA, Neoplasm; Drug Resistance, Neoplasm; Etoposide; Flow Cytometry; HL-60 Cells; Humans; Hydroxyurea; Leukemia; Melphalan; Oncogene Proteins v-abl; Protein-Tyrosine Kinases; Recombinant Proteins; Tumor Cells, Cultured | 1995 |
DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors.
Topics: Aphidicolin; Cell Division; Cell Line; Dependovirus; DNA; Etoposide; Genetic Vectors; Humans; Hydroxyurea; Topoisomerase I Inhibitors; Transformation, Genetic | 1995 |
Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Aphidicolin; Camptothecin; Carmustine; Cell Cycle; Cell Death; Cell Line; Cisplatin; Cricetinae; Cricetulus; DNA Damage; DNA Repair; DNA, Neoplasm; Doxorubicin; Drug Synergism; Etoposide; Fibroblasts; Hydroxyurea; Lung; Melphalan; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1994 |
Suppression of liver cell apoptosis in vitro by the non-genotoxic hepatocarcinogen and peroxisome proliferator nafenopin.
Topics: Animals; Apoptosis; Cells, Cultured; DNA Damage; Etoposide; Hydroxyurea; In Vitro Techniques; Liver; Liver Neoplasms, Experimental; Male; Nafenopin; Transforming Growth Factor beta | 1994 |
Chemotherapy combined with surgery in the treatment of gestational trophoblastic disease (GTD).
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Choriocarcinoma; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Resistance; Etoposide; Female; Humans; Hydatidiform Mole; Hydroxyurea; Hysterectomy; Lung Neoplasms; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Pregnancy; Salvage Therapy; Thoracotomy; Treatment Outcome; Trophoblastic Neoplasms; Uterine Hemorrhage; Uterine Neoplasms; Vincristine | 1993 |
Glomerular injury in chronic myelomonocytic leukemia.
Topics: Aged; Amyloidosis; Etoposide; Female; Humans; Hydroxyurea; Kidney Diseases; Kidney Glomerulus; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged | 1995 |
Effect of cell cycle on the regulation of the cell surface and secreted forms of type I and type II human tumor necrosis factor receptors.
Topics: Cell Cycle; Demecolcine; DNA; Enzyme Inhibitors; Etoposide; G1 Phase; G2 Phase; HeLa Cells; Humans; Hydroxyurea; Leukemia, Erythroblastic, Acute; Lymphoma, Large B-Cell, Diffuse; Mitosis; Nocodazole; Receptors, Tumor Necrosis Factor; S Phase; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vinblastine | 1995 |
ICE, mini-ICE or high-dose hydroxyurea to mobilize Philadelphia (Ph1)-negative PBPC in chronic myelogenous leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Ifosfamide; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1996 |
[Successful treatment of combined interferon-alpha and hydroxycarbamide for chronic myelogenous leukemia following therapy for malignant lymphoma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; Female; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Follicular; Middle Aged; Neoplasms, Second Primary | 1996 |
BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Carboplatin; Cell Cycle; Cell Line; Cell Survival; Etoposide; Female; Humans; Hydroxyurea; Immunoblotting; Kinetics; Mice; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Transfection; Tumor Suppressor Protein p53; Vincristine | 1996 |
Juvenile myelomonocytic leukemia: analyses of treatment results in the EORTC Children's Leukemia Cooperative Group (CLCG).
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Female; Follow-Up Studies; Humans; Hydroxyurea; Immunologic Factors; Infant; Interferons; Isotretinoin; Leukemia, Myelomonocytic, Acute; Life Tables; Male; Mercaptopurine; Remission Induction; Retrospective Studies; Splenectomy; Transplantation Conditioning; Treatment Outcome; Whole-Body Irradiation | 1996 |
Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Clone Cells; Drug Resistance, Neoplasm; Etoposide; Fluorouracil; Gamma Rays; Genes, bcl-2; Humans; Hydroxyurea; Methotrexate; Mice; Proto-Oncogene Proteins c-bcl-2; Recombinant Fusion Proteins; S Phase; Teniposide; Transfection; Vincristine | 1997 |
Apoptosis-resistant phenotype selected by alternating exposure to camptothecin and etoposide.
Topics: Antineoplastic Agents; Apoptosis; Arabinofuranosylcytosine Triphosphate; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-X Protein; Calcimycin; Camptothecin; Clone Cells; Cycloheximide; Cytarabine; DNA Fragmentation; Drug Resistance, Neoplasm; Etoposide; HL-60 Cells; Humans; Hydroxyurea; Kinetics; Nucleosomes; Phenotype; Proto-Oncogene Proteins c-bcl-2; Ultraviolet Rays | 1997 |
Salvage therapy for relapsed or refractory childhood acute lymphocytic leukemia by alternative administration a lymphoid- and myeloid-directed chemotherapeutic regimen consisting of dual modulation of ara-C, hydroxyurea, and etoposide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Fever; Gastrointestinal Diseases; Humans; Hydrocortisone; Hydroxyurea; Leucovorin; Male; Methotrexate; Mitoxantrone; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome | 1997 |
NADH dehydrogenase deficiency in an apoptosis-resistant mutant isolated from a human HL-60 leukemia cell line.
Topics: Antineoplastic Agents; Apoptosis; Calcimycin; Camptothecin; Cell Division; Clone Cells; Cloning, Molecular; Cytarabine; Deoxyglucose; Etoposide; Glucose; HL-60 Cells; Humans; Hydroxyurea; Macromolecular Substances; Mitochondria; Mutagenesis; NADH Dehydrogenase; Transcription, Genetic; Ultraviolet Rays | 1997 |
Fewer chromosome aberrations and earlier apoptosis induced by DNA synthesis inhibitors, a topoisomerase II inhibitor or alkylating agents in human cells with normal compared with mutant p53.
Topics: Alkylating Agents; Antineoplastic Agents; Aphidicolin; Apoptosis; B-Lymphocytes; Cell Division; Cell Line; Chromosome Aberrations; Cytarabine; DNA Replication; Etoposide; Humans; Hydroxyurea; Methotrexate; Mutagenesis; Nucleic Acid Synthesis Inhibitors; Radiation, Ionizing; Topoisomerase II Inhibitors; Tumor Suppressor Protein p53 | 1998 |
DNA damage induces p21 protein expression by inhibiting ubiquitination in ML-1 cells.
Topics: Acetylcysteine; Cell Nucleus; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Proteinase Inhibitors; Cytarabine; Deferoxamine; DNA Damage; Etoposide; Gene Expression Regulation; Hydroxyurea; Polyribosomes; RNA, Messenger; Tumor Cells, Cultured; Ubiquitins | 1998 |
Chemotherapy for gestational trophoblastic tumours hastens menopause by 3 years.
Topics: Adult; Antineoplastic Agents; Choriocarcinoma; Dactinomycin; Etoposide; Female; Follow-Up Studies; Humans; Hydroxyurea; Leucovorin; Menopause, Premature; Mercaptopurine; Methotrexate; Middle Aged; Pregnancy; Retrospective Studies; Risk Factors; Trophoblastic Neoplasms | 1998 |
In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Survival; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Humans; Hydroxyurea; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Methotrexate; Neoplastic Stem Cells; Tumor Cells, Cultured; Vidarabine; Vidarabine Phosphate; Vincristine | 2000 |
Regulation of DNA synthesis by the higher-order chromatin structure.
Topics: Animals; Cell Nucleus; Cell-Free System; Chromatin; Cisplatin; DNA; DNA Replication; Etoposide; Hydroxyurea; Mice; Nucleic Acid Conformation; Nucleic Acid Synthesis Inhibitors; Tumor Cells, Cultured | 2000 |
The role of p53 in death of IL-3-dependent cells in response to cytotoxic drugs.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bleomycin; Bone Marrow Cells; Cells, Cultured; Cisplatin; Colony-Forming Units Assay; DNA Damage; DNA Replication; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Floxuridine; Genes, p53; Hematopoietic Stem Cells; Hydroxyurea; Interleukin-3; Methotrexate; Mice; Mice, Inbred C57BL; Mice, Knockout; Radiation Tolerance; Tumor Suppressor Protein p53 | 2000 |
Thymidine incorporation is highly predictive of colony formation and can be used for high-throughput screening.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Survival; Chickens; CHO Cells; Colonic Neoplasms; Colony-Forming Units Assay; Cricetinae; Drug Screening Assays, Antitumor; Etoposide; Humans; Hydroxyurea; Kidney Neoplasms; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Thymidine; Tritium; Tumor Cells, Cultured | 2001 |
ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1.
Topics: Adenoviridae; Amino Acid Motifs; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Caffeine; Cell Cycle; Cell Cycle Proteins; Cell Line; Checkpoint Kinase 1; Cisplatin; Cytarabine; DNA Damage; Enzyme Activation; Etoposide; Genes, Reporter; Humans; Hydroxyurea; Immunoblotting; Nucleic Acid Synthesis Inhibitors; Phosphodiesterase Inhibitors; Phosphoric Monoester Hydrolases; Phosphorylation; Phosphoserine; Protein Kinases; Protein Serine-Threonine Kinases; Recombinant Fusion Proteins | 2001 |
Mini-ice protocol is better than high-dose hydroxyurea to mobilize Ph-negative cells in earlier phases of chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Hydroxyurea; Ifosfamide; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Treatment Outcome | 2001 |
Shunt-related abdominal metastases in an infant with medulloblastoma: long-term remission by systemic chemotherapy and surgery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cerebellar Neoplasms; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Hydrocephalus; Hydroxyurea; Infant; Liver Neoplasms; Magnetic Resonance Imaging; Male; Medulloblastoma; Neoplasm Recurrence, Local; Pelvic Neoplasms; Peritoneal Neoplasms; Remission Induction; Ventriculoperitoneal Shunt | 2001 |
Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Culture Media, Serum-Free; Cytarabine; DNA Damage; DNA Replication; Etoposide; Humans; Hydroxyurea; K562 Cells; Nucleic Acid Synthesis Inhibitors; Telomerase; Telomere; Transfection | 2002 |
Autologous peripheral blood progenitor cell transplantation with <2 x 10(6) CD34(+)/kg: an analysis of variables concerning mobilisation and engraftment.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Caspase 14; Caspases; Cerebral Hemorrhage; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Erythropoietin; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Infections; Leukapheresis; Life Tables; Male; Middle Aged; Neoplasms; Proportional Hazards Models; Transplantation Conditioning; Transplantation, Autologous | 2000 |
[Results of treatment of children with chronic myelogenous leukaemia (CML) obtained by the Polish Paediatric Leukaemia/Lymphoma Study Group].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Humans; Hydroxyurea; Infant; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mercaptopurine; Poland; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome | 2000 |
Dermatomyositis-like reaction induced by chemotherapeutical agents.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Cyclophosphamide; Dermatomyositis; Etoposide; Female; Humans; Hydroxyurea; Male | 2002 |
RAD51 is involved in repair of damage associated with DNA replication in mammalian cells.
Topics: Animals; Apoptosis; Cell Line; Cricetinae; DNA Damage; DNA Repair; DNA Replication; DNA-Binding Proteins; Dose-Response Relationship, Drug; Etoposide; Hydroxyurea; Hypoxanthine Phosphoribosyltransferase; Kinetics; Models, Genetic; Rad51 Recombinase; Recombination, Genetic; Thymidine | 2003 |
Effect of hydroxyurea and etoposide on transduction of human bone marrow mesenchymal stem and progenitor cell by adeno-associated virus vectors.
Topics: Bone Marrow Cells; Cells, Cultured; Dependovirus; DNA; Etoposide; Genetic Vectors; Humans; Hydroxyurea; Luciferases; Mesenchymal Stem Cells; Nucleic Acid Synthesis Inhibitors; Topoisomerase Inhibitors; Transduction, Genetic | 2004 |
Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cisplatin; Colonic Neoplasms; Deoxyribonucleotides; DNA Damage; Down-Regulation; Doxorubicin; Enzyme Inhibitors; Etoposide; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Hydroxyurea; Intracellular Signaling Peptides and Proteins; Protein Subunits; Proto-Oncogene Proteins; Pyridines; Recombinant Proteins; Ribonucleotide Reductases; RNA, Small Interfering; Thiosemicarbazones; Tumor Suppressor Protein p53; Vincristine | 2004 |
Human hRad1 but not hRad9 protects hHus1 from ubiquitin-proteasomal degradation.
Topics: Cell Cycle; Cell Cycle Proteins; Cell Line; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Etoposide; Exonucleases; Gene Expression Regulation; Humans; Hydroxyurea; Leupeptins; Mimosine; Models, Biological; Multienzyme Complexes; Nucleic Acid Synthesis Inhibitors; Proteasome Endopeptidase Complex; Schizosaccharomyces pombe Proteins; Ubiquitin; Up-Regulation | 2004 |
Relative cytotoxicity values at the lowest effective concentration for 12 positive chemicals in the in vitro micronucleus test utilizing Chinese hamster ovary cells.
Topics: Animals; Benz(a)Anthracenes; Bleomycin; Cell Count; Cell Survival; CHO Cells; Cricetinae; Cricetulus; Cyclophosphamide; Dactinomycin; Dose-Response Relationship, Drug; Etoposide; Female; Griseofulvin; Hazardous Substances; Hydrogen Peroxide; Hydroxyurea; Methyl Methanesulfonate; Mitomycin; Phenol; Vinblastine | 2004 |
Enhanced oligonucleotide-directed gene targeting in mammalian cells following treatment with DNA damaging agents.
Topics: Cell Count; Cell Line; DNA; DNA Damage; DNA Repair; DNA Replication; Electroporation; Etoposide; Flow Cytometry; Gene Targeting; Humans; Hydroxyurea; Mutagenesis, Site-Directed; Mutagens; Mutation; Oligonucleotides; Recombination, Genetic; Thymidine; Up-Regulation | 2004 |
DNA lesion-specific co-localization of the Mre11/Rad50/Nbs1 (MRN) complex and replication protein A (RPA) to repair foci.
Topics: Acid Anhydride Hydrolases; Blotting, Western; Camptothecin; Cations; Cell Cycle Proteins; Cell Nucleus; Comet Assay; DNA; DNA Damage; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; DNA, Single-Stranded; Etoposide; HeLa Cells; Humans; Hydroxyurea; Macromolecular Substances; Microscopy, Fluorescence; Mitomycin; Models, Biological; MRE11 Homologue Protein; Multiprotein Complexes; Nuclear Proteins; Phosphorylation; Protein Binding; Replication Protein A; Time Factors | 2005 |
Effects of adeno-associated virus DNA hairpin structure on recombination.
Topics: Aphidicolin; Base Sequence; Camptothecin; Dependovirus; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Circular; DNA, Viral; Etoposide; Genes, Reporter; Genetic Vectors; Genome, Viral; HeLa Cells; Humans; Hydroxyurea; Nucleic Acid Conformation; Recombination, Genetic; Terminal Repeat Sequences | 2005 |
TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 8; Cell Differentiation; Cell Membrane; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; GPI-Linked Proteins; Granulocytes; HL-60 Cells; Humans; Hydroxyurea; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Monocytes; Oncogene Proteins, Fusion; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Member 10c; Recombinant Fusion Proteins; Tretinoin; Tumor Cells, Cultured; Tumor Necrosis Factor Decoy Receptors; Tumor Stem Cell Assay; U937 Cells | 2005 |
Efficiency of adeno-associated virus type-2 vectors in non-human primate Schwann cells.
Topics: Analysis of Variance; Animals; Cell Count; Cell Proliferation; Cell Transplantation; Cells, Cultured; Cytomegalovirus; Demyelinating Diseases; Dependovirus; Etoposide; Fibroblasts; Gene Expression Regulation; Genetic Vectors; Green Fluorescent Proteins; Hydroxyurea; Immunohistochemistry; Macaca fascicularis; Mice; Myelin Basic Protein; Nucleic Acid Synthesis Inhibitors; Promoter Regions, Genetic; Schwann Cells; Time Factors; Transduction, Genetic | 2005 |
Monolateral renal infarction and erythromelalgia in a case of chronic myelogenous leukemia.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Erythromelalgia; Etoposide; Female; Humans; Hydroxyurea; Imatinib Mesylate; Infarction; Interferon-alpha; Kidney; Kidney Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Radiography | 2006 |
Cdc7 is an active kinase in human cancer cells undergoing replication stress.
Topics: Apoptosis; Cell Cycle Proteins; Cell Survival; Chromatin; DNA; Etoposide; HeLa Cells; Humans; Hydroxyurea; Minichromosome Maintenance Complex Component 2; Nuclear Proteins; Phosphorylation; Protein Binding; Protein Serine-Threonine Kinases; Ribonucleotide Reductases; RNA Interference; RNA, Small Interfering | 2007 |
Multiple granulocytic sarcomas in essential thrombocythemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 7; Cytarabine; Etoposide; Fatal Outcome; Female; Femoral Fractures; Femoral Neoplasms; Humans; Hydroxyurea; Middle Aged; Mitobronitol; Neoplasm Metastasis; Nitrosourea Compounds; Primary Myelofibrosis; Radiography; Sarcoma, Myeloid; Thrombocythemia, Essential | 2006 |
Replicational stress selects for p53 mutation.
Topics: Animals; Cell Proliferation; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; DNA Replication; Etoposide; Humans; Hydroxyurea; Mice; Mutation; Oncogenes; Rad51 Recombinase; Tumor Suppressor Protein p53 | 2007 |
Maternal and perinatal outcomes of first pregnancy after chemotherapy for gestational trophoblastic neoplasia in Brazilian women.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brazil; Cisplatin; Cohort Studies; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Hydroxyurea; Methotrexate; Pregnancy; Pregnancy Outcome; Retrospective Studies; Risk Factors; Vincristine | 2009 |
A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Busulfan; China; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Idarubicin; Immunosuppressive Agents; Leukemia; Leukemia, Myeloid, Acute; Male; Methylprednisolone; Mucositis; Pneumonia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Premedication; Retrospective Studies; Risk Factors; Semustine; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2009 |
Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; Chromosome Aberrations; Cohort Studies; Comorbidity; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Hydroxyurea; Immunophenotyping; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid; Male; Palliative Care; Remission Induction; Retrospective Studies; Serbia; Treatment Outcome | 2012 |
The Shu complex promotes error-free tolerance of alkylation-induced base excision repair products.
Topics: Adenine; Alkylation; Camptothecin; Cisplatin; DNA Damage; DNA Polymerase beta; DNA Repair; DNA, Fungal; Epistasis, Genetic; Etoposide; Genes, Fungal; Genetic Loci; Homologous Recombination; Humans; Hydrogen Peroxide; Hydroxyurea; Methyl Methanesulfonate; Models, Biological; Mutation; Mutation Rate; Protein Binding; Radiation, Ionizing; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Ultraviolet Rays | 2016 |
Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cells.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cellular Senescence; DNA Damage; DNA, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxyurea; Models, Biological; Mutation; Neoplasms; NF-kappa B; Signal Transduction; Tumor Suppressor Protein p53; Vidarabine | 2017 |
DNA damage response defect in Williams-Beuren syndrome.
Topics: Case-Control Studies; Cell Cycle; Cell Line; Cell Proliferation; DNA Damage; DNA Repair; Dose-Response Relationship, Drug; Etoposide; Fibroblasts; Gene Knockdown Techniques; Gene Silencing; Genetic Predisposition to Disease; Histones; Humans; Hydroxyurea; RNA, Small Interfering; Williams Syndrome | 2017 |
Skin nodules in onset of acute myeloid leukemia, a myelomonocytic variant case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cytarabine; Daunorubicin; Delayed Diagnosis; Etoposide; Fatal Outcome; Fatigue; Female; Fever; Humans; Hydroxyurea; Leukemia, Myelomonocytic, Acute; Leukemic Infiltration; Leukocytosis; Metrorrhagia; Middle Aged; Myoma; Neoplasms, Multiple Primary; Palliative Care; Skin; Uterine Neoplasms | 2017 |
SPOP is essential for DNA-protein cross-link repair in prostate cancer cells: SPOP-dependent removal of topoisomerase 2A from the topoisomerase 2A-DNA cleavage complex.
Topics: Cell Death; Cell Nucleus; DNA Cleavage; DNA Replication; DNA Topoisomerases, Type II; DNA, Neoplasm; Etoposide; Histones; Humans; Hydroxyurea; Male; Models, Biological; Mutation; Nuclear Proteins; Poly-ADP-Ribose Binding Proteins; Prostatic Neoplasms; Receptors, Androgen; Repressor Proteins; Topoisomerase Inhibitors | 2020 |
Temporal modulation of the NF-κB RelA network in response to different types of DNA damage.
Topics: Amino Acid Motifs; Amino Acid Sequence; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Chromatography, Liquid; Consensus Sequence; DNA Breaks, Double-Stranded; DNA Damage; DNA Replication; DNA, Neoplasm; Etoposide; Humans; Hydroxyurea; Osteosarcoma; Phosphorylation; Protein Interaction Maps; Protein Kinases; Protein Processing, Post-Translational; Proteomics; Tandem Mass Spectrometry; Time Factors; Transcription Factor RelA | 2021 |
Signatures of Co-Deregulated Genes and Their Transcriptional Regulators in Kidney Cancers.
Topics: Carrier Proteins; Etoposide; Humans; Hydroxyurea; Kidney Neoplasms; Protein Serine-Threonine Kinases; Signal Transduction | 2023 |